Form 3 Slover Peter T For: Jul 01 (10K)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0104
Expires:	February 28, 2011
Estimated average burden
hours per response		0.5

1. Name and Address of Reporting Person^*

Slover Peter T

(Last)

(First)

(Middle)

3115 MERRYFIELD ROW

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2009

3. Issuer Name and Ticker or Trading Symbol
ANADYS PHARMACEUTICALS INC [ANDS]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
VP, Finance and Operations

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,195 ⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Excercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Excercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	04/19/2005⁽²⁾	04/18/2014	Common Stock	2,500	$ 7.9	D
Stock Option (Right to Buy)	07/01/2005⁽³⁾	06/30/2014	Common Stock	2,000	$ 7.1	D
Stock Option (Right to Buy)	12/15/2005⁽⁴⁾	12/14/2014	Common Stock	1,850	$ 7	D
Stock Option (Right to Buy)	08/02/2006⁽⁵⁾	08/01/2015	Common Stock	3,375	$ 11.74	D
Stock Option (Right to Buy)	12/16/2006⁽⁶⁾	12/15/2015	Common Stock	2,500	$ 8.16	D
Stock Option (Right to Buy)	08/15/2007⁽⁷⁾	08/14/2016	Common Stock	10,000	$ 2.8	D
Stock Option (Right to Buy)	12/07/2007⁽⁸⁾	12/06/2016	Common Stock	5,000	$ 4.6	D
Stock Option (Right to Buy)	12/20/2006⁽⁹⁾	12/19/2016	Common Stock	2,000	$ 4.28	D
Stock Option (Right to Buy)	01/01/2008⁽¹⁰⁾	01/09/2017	Common Stock	15,000	$ 4.59	D
Stock Option (Right to Buy)	02/22/2008⁽¹¹⁾	08/21/2017	Common Stock	22,500	$ 2.29	D
Stock Option (Right to Buy)	12/07/2008⁽¹²⁾	12/06/2017	Common Stock	10,000	$ 2	D
Stock Option (Right to Buy)	12/10/2009⁽¹³⁾	12/09/2018	Common Stock	30,000	$ 1.99	D
Stock Option (Right to Buy)	07/01/2010⁽¹⁴⁾	06/30/2019	Common Stock	50,000	$ 1.86	D

Explanation of Responses:

1. Includes the following shares acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan: 670 shares acquired on May 15, 2006; 211 shares acquired on May 15, 2007; 437 shares acquired on November 15, 2007; 459 shares acquired on May 15, 2008; and 418 shares acquired on November 11, 2008.

2. 25% of the shares subject to the option became exercisable on April 19, 2005 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option became fully vested and exercisable as of April 19, 2008.

3. 25% of the shares subject to the option became exercisable on July 1, 2005 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option became fully vested and exercisable as of July 1, 2008.

4. 25% of the shares subject to the option became exercisable on December 15, 2005 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option became fully vested and exercisable as of December 15, 2008.

5. 25% of the shares subject to the option became exercisable on August 2, 2006 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of August 2, 2009.

6. 25% of the shares subject to the option became exercisable on December 16, 2006 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 16, 2009.

7. 25% of the shares subject to the option became exercisable on August 15, 2007 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of August 15, 2010.

8. 25% of the shares subject to the option became exercisable on December 7, 2007 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 7, 2010.

9. 25% of the shares subject to the option became exercisable on December 20, 2006 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 20, 2009.

10. 25% of the shares subject to the option became exercisable on January 1, 2008 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of January 1, 2011.

11. 25% of the shares subject to the option became exercisable on February 22, 2008 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next two year period such that all shares subject to the option will be fully vested and exercisable as of August 22, 2009.

12. 25% of the shares subject to the option became exercisable on December 7, 2008 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 7, 2011.

13. 25% of the shares subject to the option will become exercisable on December 10, 2009 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 10, 2012.

14. 25% of the shares subject to the option will become exercisable on July 1, 2010 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of July 1, 2013.

	/s/ Peter T Slover	07/09/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
each of Stephen T. Worland, Ph.D. and Elizabeth E. Reed, signing individually,
the undersigned's true and lawful attorneys-in fact and agents to: 
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of Anadys Pharmaceuticals,
Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder; 
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and 
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion. 
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act. 
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact shall no longer be employed by the
Company. 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 9th day of July, 2009. 

/s/ Peter T Slover
Peter T Slover

Add to Delicious

Digg It

Send by Email

View Comments (0)

Post Comment